Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials.
Paediatric HIV is a rapidly emerging disease in many resource-poor countries. Survival into adulthood is possible for HIV-infected children provided that they receive effective antiretroviral therapy (ART). Large trials comparing multiple regimens of ART in children of resource-poor countries have not been completed. Design of those trials will need to incorporate both lessons learned from trials completed in developed countries as well as unique aspects of the developing countries in which they are conducted. Trial design will necessarily include close attention to the endpoint, and in children, special consideration will need to be given to growth as a component of the endpoint--whether or not growth should be a component of the composite endpoint, and if so, how.
Benjamin
Daniel K
DK
Department of Pediatrics, Duke University, Durham, NC, USA. danny.benjamin@duke.edu
Hirschfeld
Steven
S
Cunningham
Coleen K
CK
McKinney
Ross E
RE
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic / Q000592:standards*; D003906:Developing Countries; D023381:Endpoint Determination; D006128:Growth / Q000187:drug effects* / Q000502:physiology; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans
D019380:Anti-HIV Agents